MX2021016137A - Tratamiento conjunto antineoplasico. - Google Patents

Tratamiento conjunto antineoplasico.

Info

Publication number
MX2021016137A
MX2021016137A MX2021016137A MX2021016137A MX2021016137A MX 2021016137 A MX2021016137 A MX 2021016137A MX 2021016137 A MX2021016137 A MX 2021016137A MX 2021016137 A MX2021016137 A MX 2021016137A MX 2021016137 A MX2021016137 A MX 2021016137A
Authority
MX
Mexico
Prior art keywords
combination therapy
anticancer combination
anticancer
inhibitor
combination
Prior art date
Application number
MX2021016137A
Other languages
English (en)
Inventor
Michael Gmachl
Marco Hans Hofmann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2021016137A publication Critical patent/MX2021016137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invención describe tratamientos antineoplásicos que comprenden el uso de un inhibidor de SOS1 en combinación con un inhibidor de MEK, cada uno como se describe en la presente.
MX2021016137A 2019-06-19 2020-06-17 Tratamiento conjunto antineoplasico. MX2021016137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181360 2019-06-19
PCT/EP2020/066839 WO2020254451A1 (en) 2019-06-19 2020-06-17 Anticancer combination therapy

Publications (1)

Publication Number Publication Date
MX2021016137A true MX2021016137A (es) 2022-02-21

Family

ID=66999660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021016137A MX2021016137A (es) 2019-06-19 2020-06-17 Tratamiento conjunto antineoplasico.

Country Status (12)

Country Link
US (1) US20220249492A1 (es)
EP (1) EP3986408A1 (es)
JP (1) JP2022537044A (es)
KR (1) KR20220024191A (es)
CN (1) CN114375202A (es)
AU (1) AU2020296914A1 (es)
BR (1) BR112021024532A2 (es)
CA (1) CA3142239A1 (es)
CL (1) CL2021003353A1 (es)
MX (1) MX2021016137A (es)
TW (1) TW202114683A (es)
WO (1) WO2020254451A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200111163A (ko) * 2017-12-21 2020-09-28 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
JP2024502886A (ja) 2021-01-19 2024-01-23 ルピン・リミテッド がんを処置及び／又は予防するためのｓｏｓ１阻害薬の医薬組合せ
CN113200981A (zh) * 2021-02-10 2021-08-03 杭州英创医药科技有限公司 作为sos1抑制剂的杂环化合物
WO2022212546A1 (en) * 2021-03-31 2022-10-06 Acerand Therapeutics (Usa) Limited Pyridopyrimidinone compounds
EP4319757A1 (en) 2021-04-09 2024-02-14 Boehringer Ingelheim International GmbH Anticancer therapy
EP4337678A1 (en) * 2021-05-12 2024-03-20 Revolution Medicines, Inc. Use of sos1 inhibitors with mtor inhibitors to treat cancers
CN117957224A (zh) * 2021-08-03 2024-04-30 苏州信诺维医药科技股份有限公司 稠环化合物、药物组合物及其应用
CN115417868B (zh) * 2021-09-13 2024-04-02 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的杂环化合物及其用途
CN117957226A (zh) * 2021-09-17 2024-04-30 南京再明医药有限公司 作为sos1抑制剂的杂环化合物及其用途
CN115057847B (zh) * 2022-07-26 2024-01-26 山东百启生物医药有限公司 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6431770B2 (ja) 2012-03-14 2018-11-28 ルピン・リミテッド Ｍｅｋインヒビターとしてのヘテロシクリル化合物
EP3558979B1 (en) * 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
KR20200111163A (ko) 2017-12-21 2020-09-28 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체

Also Published As

Publication number Publication date
JP2022537044A (ja) 2022-08-23
CA3142239A1 (en) 2020-12-24
US20220249492A1 (en) 2022-08-11
CL2021003353A1 (es) 2022-09-30
CN114375202A (zh) 2022-04-19
TW202114683A (zh) 2021-04-16
KR20220024191A (ko) 2022-03-03
WO2020254451A1 (en) 2020-12-24
BR112021024532A2 (pt) 2022-05-24
AU2020296914A1 (en) 2021-12-23
EP3986408A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
MX2021016137A (es) Tratamiento conjunto antineoplasico.
PH12019502235A1 (en) Anticancer combination therapy
MX2013007773A (es) Terapia anticancer con inhibidores duales de aurora quinasa / mek.
PH12019502291A1 (en) Anticancer combination therapy
MX2019003938A (es) Compuestos espirociclicos.
MY178607A (en) Panel interconnectable with similar panilar for forming a covering
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
MX2017012553A (es) Compuestos espirociclicos.
MX2021014905A (es) Células seguras e invisibles para el sistema inmunitario.
MX2016011244A (es) Tarjeta de funcion dual, con funcionalidad de tarjeta llave y funcionalidad de tarjeta de valores acumulados.
IL288237A (en) Combined treatment
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
GB201906864D0 (en) Combination therapy
IL286700A (en) Combined treatment against cancer
PH12021550101A1 (en) Cardio- and renosafe antidiabetic therapy
GB202105349D0 (en) looksin.com
GB201914470D0 (en) H.e.r.o iv
IL289130A (en) Combined treatment
GB202012692D0 (en) Kodugo.com
EA201992273A1 (ru) Противораковая комплексная терапия
CA191904S (en) Display unit